Correlation of High-Risk Soft Tissue Sarcoma Biomarker Expression Patterns with Outcome following Neoadjuvant Chemoradiation
Authors:
Open Access
Abstract
Background.Sarcoma mortality remains high despite adjuvant chemotherapy. Biomarker predictors of treatment response and outcome could improve treatment selection.Methods. Tissue microarrays (TMAs) were created using pre- and posttreatment tumor from two prospective trials (MGH pilot and RTOG 9514) of neoadjuvant/adjuvant MAID chemotherapy and preoperative radiation. Biomarkers were measured using automated computerized imaging (AQUA or ACIS). Expression was correlated with disease-free survival (DFS), distant disease-free survival (DDFS), and overall survival (OS).Results. Specimens from 60 patients included 23 pretreatment (PRE), 40 posttreatment (POST), and 12 matched pairs (MPs). In the MP set, CAIX, GLUT1, and PARP1 expression significantly decreased following neoadjuvant therapy, but p53 nuclear/cytoplasmic (N/C) ratio increased. In the PRE set, no biomarker expression was associated with DFS, DDFS, or OS. In the POST set, increased p53 N/C ratio was associated with a significantly decreased DFS and DDFS (HR 4.13,; HR 4.16,), while increased ERCC1 and XPF expression were associated with an improved DFS and DDFS. No POST biomarkers were associated with OS.Conclusions. PRE biomarker expression did not predict survival outcomes. Expression pattern changes after neoadjuvant chemoradiation supports the concepts of tumor reoxygenation, altered HIF-1αsignaling, and a p53 nuclear accumulation DNA damage response.Clinical Trial Registration. NRG Oncology RTOG 9514 is registered with ClinicalTrials.gov. The ClinicalTrials.gov Identifier isNCT00002791.
Keywords
Funding Information
- National Cancer Institute (U10CA21661, U10CA180868, U10CA180822, U10CA37422, U24CA180803)
- National Cancer Institute (U10CA21661, U10CA180868, U10CA180822, U10CA37422, U24CA180803)
- National Cancer Institute (U10CA21661, U10CA180868, U10CA180822, U10CA37422, U24CA180803)
- National Cancer Institute (U10CA21661, U10CA180868, U10CA180822, U10CA37422, U24CA180803)
- National Cancer Institute (U10CA21661, U10CA180868, U10CA180822, U10CA37422, U24CA180803)
- Pennsylvania Department of Health (U10CA21661, U10CA180868, U10CA180822, U10CA37422, U24CA180803)
This publication has 45 references indexed in Scilit:
- p53-Mediated Senescence Impairs the Apoptotic Response to Chemotherapy and Clinical Outcome in Breast CancerCancer Cell, 2012
- Topoisomerase II-alpha protein expression and histological response following doxorubicin-based induction chemotherapy predict survival of locally advanced soft tissues sarcomasEuropean Journal of Cancer, 2011
- Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysisBreast Cancer Research and Treatment, 2010
- Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: A one transcription factor (HIF-1) show?Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2009
- Hypoxia-driven selection of the metastatic phenotypeCancer and Metastasis Reviews, 2007
- Carbonic Anhydrase IX as a Marker for Poor Prognosis in Soft Tissue SarcomaClinical Cancer Research, 2004
- Tissue microarrays for high-throughput molecular profiling of tumor specimensNature Medicine, 1998
- Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1αGenes & Development, 1998
- Prognostic value of immunohistochemistry for p53 in primary soft-tissue sarcomas: a multivariate analysis of five antibodiesJournal of Cancer Research and Clinical Oncology, 1997
- Prognostic value of Ki‐67 expression in 182 soft tissue sarcomas. Proliferation — a marker of metastasis?APMIS, 1994